Results: Compared to the Vehicle, all treatments significantly reduced (p<0.001) arthritic score with a reduction of the arthritic score evaluated between 40% (for methotrexate) and 70% (for diclofenac) (figure 1. Compared to the vehicle, the radiographic score was improved by Naproxene, Diclofenac, Celecoxib, Glucocorticoids, Etanercept (p<0.001) but not by methotrexate. Compared to Etanercept, Naproxene and diclofenac showed less radiological structural changes (p<0.01) (figure 2). Conclusions: Our study demonstrates for the first time that an early treatment with NSAIDs, excluding COX2 selective inhibitor, is more beneficial than Etanercept on the radiological damages in adjuvant induced arthritis. The close efficacy of all drugs on the arthritis score suggests that the beneficial impact of NSAID is not only driven by their impact on the systemic inflammation. NSAIDs should be used during the window of opportunity. Background: P. gingivalis is a Gram-negative anaerobic bacterium usually located in the oral cavity, as component of microbiome. Next to the established association with oral cavity diseases, such as periodontitis and halitosis, in the last years a growing interest has been addressed to its implication in the development of autoimmune diseases, such as Rheumatoid Arthritis (RA). The ability of P. gingivalis to citrullinate peptides is the most relevant link with RA. Indeed, this bacterium has several virulence factors directly contributing to its chronic inflammation regardless of citrullination. Data from the literature demonstrated the ability of P. gingivalis in inducing the production of several inflammatory cytokines, such as TNF, IL6 and IL17, through the TLR signaling pathways. Objectives: In the present case-control study, we aimed at analysing tongue microbiome in a large RA cohort, focusing on the evaluation of P. gingivalis presence and quantification. Methods: We enrolled 143 RA patients (1987 ACR criteria; M/F 32/111, mean±SD age 57.5±19.8 years, mean±SD disease duration 155.9±114.7 months); 36 periodontitis (M/F 11/25, mean±SD age 56±9.9 years, mean±SD disease duration 25.5±20.9 months); 57 (M/F 12/45, mean ±SD age 61.4±10.9 years, mean ±SD disease duration 62.3±66.9 months) affected by knee osteoarthritis or fibromyalgia (control subjects -CS). All subjects underwent a clinical evaluation in order to assess disease activity by DAS28. Blood serum samples were obtained to evaluate the presence of ACPA by a commercial ELISA kit. Finally, a standard cytologic swab to collect tongue biofilm samples was performed and the presence of P. gingivalis was evaluated by PCR method. Results: The prevalence of P. gingivalis resulted significantly higher in RA and PD patients in comparison with CS (P=0.01 and P=0.003, respectively). No correlation between bacterium presence and ACPA was found. When evaluating the percentage of P. gingivalis on the total tongue biofilm, we observed a significant correlation between this measure and DAS28 values (r=0.4, P=0.01). Furthermore, RA patients in DAS28 remission showed a significantly lower prevalence of P. gingivalis in comparison with non-remission patients (P=0.02). Conclusions: In the present study, for the first time we assessed the prevalence of P. gingivalis, i.e. its percentage on the total tongue biofilm, in a large RA cohort. A significant correlation between the amount of P. gingivalis on total tongue biofilm and disease activity was observed. There was no association with ACPA, suggesting that this bacterium, beyond citrullination, could be implicated in triggering a pro-inflammatory state in RA. 
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Conclusions:
Serum from RA patients in our series significantly reacted against different HERV-K peptides in comparison to the general population suggesting a role for the HERV-K related, secondary antigenic driven immune response in the pathogenesis of RA. Further studies are needed to confirm these results and to explore the role of HERV-K surface peptides as potential therapeutic targets. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.2043 
